ABL Diagnostics, a leading international company listed on Euronext (FR001400AHX6 – ABLD), has announced the signing of an exclusive distribution agreement with AB ANALITICA (https://www.abANALITICA.com/en/), a company specializing in the development and sale of diagnostic systems for professional use. Under this agreement, AB ANALITICA will have the rights to promote and sell ABL Diagnostics’ molecular biology assays and software systems to laboratories across Italy.
The partnership will focus on PCR assays and downstream analysis systems for infectious diseases such as HIV, Viral Hepatitis, and Respiratory Viruses, using Capillary Electrophoresis (SANGER) or Next Generation Sequencing (NGS) workflows. With its expertise in molecular biology and a strong presence in Italy since 1990, AB ANALITICA is well-positioned to provide high-quality solutions to laboratories throughout the country.
“We are excited to add ABL Diagnostics’ portfolio to our offerings and provide our clients with innovative solutions for Microbiology Genotyping through DNA sequencing,” said Alberto Bortolato, Sales and Business Development Manager at AB ANALITICA.
ABL Diagnostics’ Head of Diagnostics, Dimitri Gonzalez, also expressed enthusiasm for the partnership, stating, “Our network of distributors has been expanding for over a decade. We are delighted to welcome AB ANALITICA on board and together, offer robust and comprehensive solutions to laboratories in Italy seeking simple and innovative sequencing-based solutions.”
The detailed terms of the agreement have not been disclosed.
ABOUT ABL DIAGNOSTICS
ABL Diagnostics S.A. (ABLD) is a global company that offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection and genotyping. Their products cover a wide range of microbiology applications, including HIV, SARS-CoV-2, Tuberculosis, viral hepatitis, and more. ABL Diagnostics’ products are distributed worldwide through its own sales team and a network of exclusive distributors. The company also develops and markets kits for clinical specimen collection and digital solutions such as Nadis®, an electronic medical record system used in over 200 hospitals in France.
ABOUT AB ANALITICA
Founded in 1990, AB ANALITICA specializes in the development and sale of diagnostic systems for professional use. The company has a team of highly qualified researchers and collaborates with research institutes, universities, and hospitals to develop high-quality, innovative, and safe diagnostic systems. Their expertise includes diagnostics based on qualitative and quantitative determination of nucleic acids, biobanking management systems, in vivo and in vitro diagnostics using breath tests and stable isotopes. AB ANALITICA is certified according to UNI EN ISO 9001 and UNI EN ISO 13485 for the design, development, production, and trade of in-vitro diagnostic medical devices.
For more information, please visit www.abldiagnostics.com.
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. Such forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, and they are subject to numerous risks. The occurrence of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from the forward-looking statements.
This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe for ABL Diagnostics shares. The distribution of this press release in certain countries may be a breach of applicable laws. Those in possession of this press release must inquire about any local restrictions and comply with them.
Distributed by https://pressat.co.uk/
